Journal of Heart and Lung Transplantation

IL-33 mediates Pseudomonas induced airway fibrogenesis and is associated with CLAD.  42:53-63. 2023

Contemporary trends in PGD incidence, outcomes, and therapies.  41:1839-1849. 2022

Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction.  41:1773-1780. 2022

ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery.  41:1135-1194. 2022

Practice variation in the diagnosis of acute rejection among pediatric heart transplant centers: An analysis of the pediatric heart transplant society (PHTS) registry.  40:1550-1559. 2021

N-myc-interactor mediates microbiome induced epithelial to mesenchymal transition and is associated with chronic lung allograft dysfunction.  40:447-457. 2021

Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease.  40:351-358. 2021

Pregnancy after heart transplantation: A second-generation transmission of the gift of life—in reply.  40:235. 2021

International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation.  39:1171-1190. 2020

Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis.  39:904-914. 2020

A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation.  39:627-635. 2020

Center and Donor Factors Associated with Discrepant Responses to Donor Lung Offers.  39:S140. 2020

Clinical Characteristics and Outcomes of Patients Requiring Prolonged Inotropes after Left Ventricular Assist Device Implantation.  39:S445-S446. 2020

Combined Thoracic-Kidney Transplantation Practices May Exacerbate Existing Geographic Disparities in Access to Deceased Donor Kidney Transplantation.  39:S366-S367. 2020

Gender Differences in Early Mortality after LVAD: An IMACS Analysis.  39:S108. 2020

Health-Related Quality of Life Differs by Pre-Operative Implant Strategy from before through Mid-Term after Surgery: Findings from INTERMACS.  39:S208. 2020

Implications of ECMO Bridging and Salvage Strategies on Mortality and PGD.  39:S103-S104. 2020

Incidence and Onset of Leukopenia in Adults the First Year after Orthotopic Heart Transplantation.  39:S274. 2020

Multi-Center Validation of a Consensus-Based Scoring Guide for Evaluating Donor Lung Offers.  39:S216. 2020

Persistent Mitral Regurgitation after Left Ventricular Assist Device: A Clinical Conundrum.  39:S402. 2020

Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis.  39:342-352. 2020

The Cost and Length of Stay Associated with Biventricular Assist Devices in the United States (2009-2015).  39:S400-S401. 2020

The Fontan Liver after Cardiac Transplantation.  39:S67. 2020

True, maybe true, perhaps unrelated – granulocyte colony-stimulating factor and increased risk of rejection in heart transplant recipients.  39:403. 2020

American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support.  39:187-219. 2020

Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: An IMACS registry propensity matched analysis.  39:145-156. 2020

Pathological insights into persistent mitral regurgitation following continuous flow left ventricular assist device implantation.  39:184-186. 2020

Pregnancy outcomes in women with cardiothoracic transplants: A Systematic review and meta-analysis.  39:93-102. 2020

Differences in health-related quality of life by implant strategy: Analyses from the Interagency Registry for Mechanically Assisted Circulatory Support.  39:62-73. 2020

Blood pressure in a mechanically assisted circulation: “Heat, spirit, perfection”.  38:406-407. 2019

Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry.  38:364-373. 2019

Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model.  38:456-465. 2019

Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry.  38:408-417. 2019

Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices.  38:352-363. 2019

Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.  37:1207-1217. 2018

Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality.  37:1013-1020. 2018

Second annual report from the ISHLT Mechanically Assisted Circulatory Support Registry.  37:685-691. 2018

Distal airway microbiome is associated with immunoregulatory myeloid cell responses in lung transplant recipients.  37:206-216. 2018

Practical application of gene expression arrays in a clinical setting: The light at the end of a long tunnel.  36:1178-1179. 2017

Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.  36:1121-1136. 2017

Characteristics of lung allocation score exception requests submitted to the national Lung Review Board.  36:812-814. 2017

Use of a novel pulmonary artery cannula to provide extracorporeal membrane oxygenation as a bridge to lung transplantation.  35:1051-1053. 2016

Evaluation of the effect of diminished pulsatility as seen in continuous flow ventricular assist devices on arterial endothelial cell phenotype and function.  35:930-932. 2016

Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure.  35:795-807. 2016

The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.  35:500-507. 2016

Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study.  35:301-305. 2016

Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold.  34:1198-1207. 2015

Exercise physiology, testing, and training in patients supported by a left ventricular assist device.  34:1005-1016. 2015

Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor.  34:329-337. 2015

Adult cardiothoracic transplant nursing: An ISHLT consensus document on the current adult nursing practice in heart and lung transplantation.  34:139-148. 2015

Lung size mismatch and primary graft dysfunction after bilateral lung transplantation.  34:233-240. 2015

Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study.  33:1304-1311. 2014

A multi-institutional study of malignancies after heart transplantation and a comparison with the general United States population.  33:478-485. 2014

Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: Risk factors, diagnosis, and treatment.  33:878-887. 2014

Single-center experience with extracorporeal photopheresis in pediatric heart transplantation.  33:624-628. 2014

Disparities in lung transplantation before and after introduction of the lung allocation score.  32:684-692. 2013

Factors associated with stress and coping at 5 and 10 years after heart transplantation.  32:437-446. 2013

Retransplantation as a successful therapy for post-transplant protein-losing enteropathy.  32:472-473. 2013

VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.  32:120-128. 2013

Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey.  31:1102-1108. 2012

A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.  31:942-949. 2012

Rapidly progressive pulmonary venoocclusive disease in young women taking oral contraceptives.  31:1031-1036. 2012

Opportunities for improvement in heart transplantation outcomes for young adults 18 to 35 years of age.  31:903-904. 2012

116 Gastrointestinal Bleeding Risk in Patients with Ventricular Assist Devices.  31:s47-s48. 2012

Comparison of risk factors and outcomes for pediatric patients listed for heart transplantation after bidirectional Glenn and after Fontan: An analysis from the Pediatric Heart Transplant Study.  31:133-139. 2012

Use of sublingual tacrolimus in lung transplant recipients.  31:127-132. 2012

Older patients (age 65+) report better quality of life, psychological adjustment, and adherence than younger patients 5 years after heart transplant: A multisite study.  31:478-484. 2012

Allosensitization and outcomes in pediatric heart transplantation.  30:1221-1227. 2011

Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol.  30:879-887. 2011

The role of fibrinolytic genes and proteins in the development of allograft vascular disease.  30:935-944. 2011

Report from a consensus conference on antibody-mediated rejection in heart transplantation.  30:252-269. 2011

Minimizing infection and rejection death: Clues acquired from 19 years of multi-institutional cardiac transplantation data.  30:151-157. 2011

Mitral valve prolapse after long-term mechanical ventricular unloading.  30:1067-1068. 2011

Construct validity of the definition of primary graft dysfunction after lung transplantation.  29:1231-1239. 2010

Balancing rejection and infection with respect to age, race, and gender: Clues acquired from 17 years of cardiac transplantation data.  29:966-972. 2010

Clinical management of continuous-flow left ventricular assist devices in advanced heart failure.  29:1081. 2010

On solid-phase antibody assays.  29:1207-1209. 2010

Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates.  29:1034-1038. 2010

Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.  29:1009-1013. 2010

Outcomes of Pediatric Patients With Hypertrophic Cardiomyopathy Listed for Transplant.  28:1329-1334. 2009

Transforming Growth Factor-beta Polymorphisms and Cardiac Allograft Rejection.  28:1057-1062. 2009

Symptom Frequency and Distress from 5 to 10 Years After Heart Transplantation.  28:759-768. 2009

Safety and Efficacy of Ibutilide in Heart Transplant Recipients.  28:505-507. 2009

The 15-Step Oximetry Test: a Reliable Tool to Identify Candidates for Lung Transplantation Among Patients With Idiopathic Pulmonary Fibrosis.  28:328-333. 2009

Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation.  28:213-225. 2009

Intraoperative Evaluation of the HeartMate II Flow Estimator.  28:39-43. 2009

Human, Bovine and Porcine Systematic Vascular Input Impedances Are Not Equivalent: Implications for Device Testing and Xenotransplantation in Heart Failure.  27:1340-1347. 2008

Patient With Hypofibrinolysis-mediated Thromboembolism Converted to a Hypercoagulable/Hyperfibrinolytic State via Ventricular Assist Device Placement.  27:1169-1171. 2008

Amiodarone Pulmonary Toxicity After Lung Transplantation.  27:1059-1063. 2008

Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension.  27:780-788. 2008

Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy.  27:610-615. 2008

Use of an Intraperitoneal Ventricular Assist Device With a Polytetrafluoroethylene Barrier Decreases Infections.  27:268-271. 2008

Role for CD4⁺CD25⁺ T Cells in Inhibition of Graft Rejection by Extracorporeal Photopheresis.  27:616-622. 2008

Fatal Diffuse Alveolar Damage in Two Lung Transplant Patients Treated With Cetuximab.  26:1340-1344. 2007

Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation.  26:1182-1191. 2007

Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression Pattern.  26:494-497. 2007

Patterns and Predictors of Quality of Life at 5 to 10 Years After Heart Transplantation.  26:535-543. 2007

A Wireless Pressure Sensor for Monitoring Pulmonary Artery Pressure in Advanced Heart Failure: Initial Experience.  26:85-88. 2007

Acute take-off of the right coronary artery with long intra-aortic wall course presenting as chronic coronary ostium occlusion in a patient with end-stage heart failure.  25:740-742. 2006

Argatroban, Bivalirudin, and Lepirudin do not Decrease Clot Propagation and Strength as Effectively as Heparin-activated Antithrombin In Vitro.  25:653-663. 2006

Improving clinical practice: Should we give influenza vaccinations to heart transplant patients?.  25:320-323. 2006

Rejection with hemodynamic compromise: Objective evidence for efficacy of photopheresis.  25:283-288. 2006

Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study.  25:271-275. 2006

Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006.  25:1043-1056. 2006

Predictors of physical functional disability at 5 to 6 years after heart transplantation.  24:2279-2285. 2005

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.  24:2196-2201. 2005

Who returns to work after heart transplantation?.  24:2255-2261. 2005

Multi-organ transplantation: Is there a protective effect against acute and chronic rejection?.  24:1828-1833. 2005

The intensive care unit oxygen challenge should not be used for donor lung function decision-making.  24:1902-1905. 2005

Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: Multi-institutional study of post-operative weight change.  24:1424-1430. 2005

Predictors of quality of life at 5 to 6 years after heart transplantation.  24:1431-1439. 2005

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.  24:517-525. 2005

Of mice and men: Mouse models and the molecular mechanisms of post-transplant coronary artery disease.  24:2003-2014. 2005

Re-stenosis of a sirolimus-coated stent in a heart transplant recipient with allograft vasculopathy.  24:1444.e9-1444.e11. 2005

The case for selective re-issuance of medical certificates to allow pilots who have received a heart transplant to resume flying.  24:259-269. 2005

To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?.  24:392-400. 2005

Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.  24:222-225. 2005

Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients.  23:110-114. 2004

Retransplantation in 7,290 primary transplant patients: A 10-year multi-institutional study.  22:862-868. 2003

Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease.  22:515-518. 2003

Change in quality of life from before to after discharge following left ventricular assist device implantation.  22:322-333. 2003

Change in quality of life from after left ventricular assist device implantation to after heart transplantation.  22:1254-1267. 2003

Aortic graft transplantation in mice.  21:1319-1321. 2002

PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model.  21:1314-1318. 2002

Mechanical circulatory support for myocarditis: How much recovery should occur before device removal?.  21:1246-1249. 2002

Cardiac transplant patients response to the ³¹P MRS stress test.  21:522-529. 2002

Indefinite allograft survival mediated by donor bone marrow is dependent on the presence of a functional CD95 (Fas) gene in recipients.  20:1132-1135. 2001

Peter Medawar and the science of transplantation: A parable.  20:927. 2001

Cardiomyopathy in a carrier of Duchenne's muscular dystrophy.  20:781-784. 2001

Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation.  20:657-669. 2001

Cardiac transplant outcome of patients supported on left ventricular assist device vs intravenous inotropic therapy.  20:449-456. 2001

A multi-institutional study of cardiac retransplantation: incidence, risk factors for mortality, and outcome..  20:181. 2001

Differential modulation of alloreactive T cell receptor expression induced by allogeneic bone marrow and splenocyte infusions..  20:172. 2001

The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience..  20:167-168. 2001

Who is most likely to enjoy long term survival after cardiac transplantation? Risk stratification in a 10 year multi-institutional experience..  20:168-169. 2001

The utility of open lung biopsy following lung transplantation.  19:852-857. 2000

Activities of daily living among heart transplant candidates: Neuropsychological and cardiac function predictors.  19:995-1006. 2000

Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indices.  18:750-763. 1999

Donor management, organ preservation, organ distribution coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: Patterns and contributing factors.  18:239-247. 1999

Predictors of quality of life in patients at one year after heart transplantation.  18:202-210. 1999

Protective effects of Celsior in lung transplantation.  18:320-327. 1999

Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors.  17:744-753. 1998

Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database..  17:744-753. 1998

Patient compliance at one year and two years after heart transplantation.  17:383-394. 1998

Risk of death or incapacitation after heart transplantation, with particular reference to pilots.  17:497-504. 1998

Infection after pediatric heart transplantation: Results of a multiinstitutional study.  16:1207-1215. 1997

Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-α, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients.  16:1046-1053. 1997

Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate.  16:813-821. 1997

The incremental risk of female sex in heart transplantation: A multiinstitutional study of peripartum cardiomyopathy and pregnancy.  16:801-812. 1997

Symptom distress three months after heart transplantation.  16:604-614. 1997

Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database..  16:813-821. 1997

The incremental risk of female sex in heart transplantation: a multiinstitutional study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group..  16:801-812. 1997

Competing outcomes after heart transplantation: A comparison of eras and outcomes.  16:190-198. 1997

Improvement in quality of life in patients with heart failure who undergo transplantation.  15:749-757. 1996

Impact of the heart transplant waiting process on spouses.  15:623-630. 1996

Poststorage diastolic abnormalities of heart transplants: Is vascular dysfunction or myocardial contracture the culprit?.  15:461-469. 1996

Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study.  15:329-341. 1996

Semiquantitative measurement of cytokine messenger RNA in endomyocardium and peripheral blood mononuclear cells from human heart transplant recipients.  15:206-217. 1996

Evaluation of a new preservation solution: Celsior in the isolated rat lung.  14:601-604. 1995

The high risk heart donor: Potential pitfalls.  14:424-428. 1995

Evaluation of a new preservation solution: Celsior in the isolated rat lung. Paris-Sud University Lung Transplatation Group..  14:601-604. 1995

Predictors of quality of life in patients with advanced heart failure awaiting transplantation.  14:2-10. 1995

Predictors of quality of life in patients with advanced heart failure awaiting transplantation..  14:2-10. 1995

Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis.  14:409-418. 1995

Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group..  14:409-418. 1995

Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.  14:856-864. 1995

Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation.  13:958-962. 1994

Treatment of recurrent heart rejection with mycophenolate mofetil (RS- 61443): Initial clinical experience.  13:444-450. 1994

Cytomegalovirus after heart transplantation. Risk factors for infection and death: A multiinstitutional study.  13:394-404. 1994

Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group..  13:394-404. 1994

Infection after heart transplantation: A multiinstitutional study.  13:381-393. 1994

Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group..  13:381-392. 1994

Influence of HLA mismatch on rejection after heart transplantation: A multiinstitutional study.  13:583-596. 1994

Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group..  13:583-595. 1994

Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: A multivariable, multiinstitutional report.  13:353-365. 1994

Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group..  13:353-364. 1994

Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants.  12:1053-1061. 1993

Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants..  12:1053-1061. 1993

Pretransplantation risk factors for acute rejection after heart transplantation: A multiinstitutional study.  12:355-366. 1993

Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group..  12:355-366. 1993

Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study.  12:549-562. 1993

Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group..  12:549-562. 1993

Total lymphoid irradiation: is there a role in pediatric heart transplantation?.  12:S293-S300. 1993

Methotrexate pulse therapy in the treatment of recurrent acute heart rejection.  11:1116-1124. 1992

Cyclosporine blood monitoring after heart transplantation: A prospective comparison of monoclonal and polyclonal radioimmunoassays.  11:522-529. 1992

Cyclosporine blood monitoring after heart transplantation: a prospective comparison of monoclonal and polyclonal radioimmunoassays..  11:522-529. 1992

Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation.  11. 1992

Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation..  11:S232-S236. 1992

Donor cerebral emboli as a cause of acute graft dysfunction in lung transplantation.  11:72-76. 1992

Donor cerebral emboli as a cause of acute graft dysfunction in lung transplantation..  11:72-76. 1992

Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart.  11:584-586. 1992

Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart..  11:584-586. 1992

Total lymphoid irradiation in the treatment of early or recurrent heart rejection.  11:902-912. 1992

Pulmonary vascular resistance and the risk of heart transplantation.  7:331-336. 1988